Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

BUPA Launches Breakthrough Treatment For Back And Knee Pain
New research reveals around 22 million people suffered back pain in the last year - just under half of all UK adults (45 percent)[1]. More than one in four UK adults - nearly 13 million people - suffered from knee pain in the last year. Over 80 percent of the people with back or knee pain still suffer some pain after undergoing treatment recommended by a healthcare professional. Bupa is making APOS Treatment for knee and lower back pain available in the UK for the first time. The breakthrough treatment can eliminate the need for prescription pain relief for seven out of 10 people[2].
generic viagra online
Blood Pressure Association Comment - Food Standards Agency Revised Salt Targets
UK charity the Blood Pressure Association has responded to the publication of revised salt reduction targets by the Food Standards Agency:
News of the day
HydroCision Introduces The "Walk In/Walk Out" Option For Treatment Of Herniated Discs
HydroCision Inc. announced the launch of its new SpineJet® Percutaneous Access Set for use in herniated disc procedures using its novel cutting-with-water fluidjet technology. "These instruments will assist the company to more quickly capitalize on the double digit growth of the minimally invasive percutaneous discectomy market," says Doug Daniels. "A large driver of procedural growth has been patients who seek out surgeons who perform minimally invasive procedures to reduce down time from work in these tough economic times. This has led to rapid adoption of this new and evolving technique for the treatment of lower back pain by a growing number of neurosurgeons, orthopedic surgeons and interventional pain physicians. This trend has created the need for new instruments that can work through very small incisions."
Mental Health

Kohl Bill Would Save Consumers $3.5 Billion Per Year, According To FTC, USA

U.S. Senator Herb Kohl released the following statement on the announcement from U.S. Federal Trade Commission Chairman Jon Leibowitz that banning pay-for-delay settlements that keep generic drugs off the market would save consumers at least $3.5 billion per year and provide significant cost savings for federal government, which pays approximately one-third of all prescription drug costs. Senator Kohl"s bill, the Preserve Access to Affordable Generic Drugs Act (S. 369), would prohibit the anti-consumer practice of brand-name drug manufacturers using pay-off agreements to keep cheaper generic equivalents off the market. Introduced in February with Senators Chuck Grassley (R-IA), Russ Feingold (D-WI), Dick Durbin (D-IL) and Amy Klobuchar (D-MN), the bill is scheduled to be marked up by the Senate Judiciary Committee. "This morning, FTC Chairman Jon Leibowitz announced that putting an end to pay-for-delay deals between drug companies would save Americans $3.5 billion a year. These payoffs create an excessive and unreasonable barrier to the drug treatments people need by allowing brand pharmaceutical companies to pay off their generic competition to keep them out of the market. We cannot profess to care about the high cost of prescription drugs, while turning a blind eye to anti-competitive backroom deals between brand and generic drug companies that only serve the companies involved. I urge my colleagues to support my legislation to ban these settlements once and for all." Special Committee on Aging Senator Herb Kohl, Chair


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009